Brain‐Derived Tau as an Outcome Marker in Guillain‐Barré Syndrome: A Retrospective Cohort Study
BD-tau at GBS onset is associated with long-term outcome but not disease severity. Because BD-tau is essentially a CNS biomarker, our results suggest that CNS involvement influences recovery.
Authors
- Jan Lycke (ORCID: https://orcid.org/0000-0002-7891-8466)
- Igal Rosenstein (ORCID: https://orcid.org/0000-0002-5078-9690)
- Fernando González‐Ortiz (ORCID: https://orcid.org/0000-0001-7897-9456)
- Markus Axelsson (ORCID: https://orcid.org/0000-0003-2036-4007)
- Brynhildur Hafsteinsdóttir (ORCID: https://orcid.org/0000-0001-7889-8453)
- Tomas Bergström (ORCID: https://orcid.org/0000-0002-9257-6757)
- Lenka Novakova (ORCID: https://orcid.org/0000-0001-7899-6395)
- Henrik Zetterberg (ORCID: https://orcid.org/0000-0003-3930-4354)
- Kaj Blennow
- Nina Gleisner
- Ellen Alpsten
Institutions
- University of Science and Technology of China (CN)
- University of Wisconsin–Madison (US)
- Sahlgrenska University Hospital (SE)
- Sorbonne Université (FR)
- Region Västra Götaland (SE)
- Pitié-Salpêtrière Hospital (FR)
- UK Dementia Research Institute (GB)
- Institut du Cerveau (FR)
- University College London (GB)
- University of Gothenburg (SE)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1111/ene.70155
- Citations
- 1
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Rune och Ulla Amlövs Stiftelse för Neurologisk och Reumatologisk Forskning
- Göteborgs Läkaresällskap
- Stiftelsen Edit Jakobssons Donationsfond
- Neuroförbundet